Full Press Release Details
Summit Therapeutics plc
(‘Summit’ or the ‘Company’)
Summit Therapeutics to Present at Upcoming Conferences
Oxford, UK, and Cambridge, MA, US, 18 March 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that management will present at two upcoming conferences.
Details of the conference presentations:
Superbugs & Superdrugs 2019: The Development of Precision Antibiotics: Agents Designed to Meet the Demands of Stewardship, on 18 March 2019 at 1:40pm GMT in London
Oppenheimer 29th Annual Healthcare Conference: corporate presentation on 20 March 2019 at 2:10pm EDT in New York City
A live webcast of the Oppenheimer presentation will be available in the Investors section of the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation.
About Summit Therapeutics
| Summit | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: | 44 (0)1235 443 951 |
| Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP (Nominated Adviser) | Tel: | +44 (0)20 7213 0880 |
| Liam Murray / Tony Rawlinson | ||
| N+1 Singer (Joint Broker) | Tel: | +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer, Corporate Finance Tom Salvesen, Corporate Broking | ||
| Bryan Garnier & Co Limited (Joint Broker) | Tel: | +44 (0)20 7332 2500 |
| Phil Walker / Dominic Wilson | ||
| MSL Group (US) | Tel: | +1 781 684 6557 |
| Jon Siegal | summit@mslgroup.com | |
| Consilium Strategic Communications (UK) | Tel: | +44 (0)20 3709 5700 |
| Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / | summit@consilium-comms.com | |
| Lindsey Neville |